Study | Studies included until | Outcome | N studies | Result OR/RR (95% CI)a |
---|---|---|---|---|
Any mental disorder | ||||
Fond et al., 2021 [7] | 12 February 2021 | Death, OR | 21 | 1.38 (1.15–1.65), adjusted |
Liu et al., 2021 [8] | 7 July 2021 | Death, OR | 28 | 1.47 (1.26–1.72) |
Toubasi et al., 2021 [9] | 15 February 2021 | Death + severity, OR | 5 | 1.52 (1.20–1.93), fully adjusted |
Vai et al., 2021 [10] | 5 March 2021 | Death, OR | 21 | 2.00 (1.58–2.54) |
Serious (severe) mental disorder | ||||
Fond et al., 2021 [7] | 12 February 2021 | Death, OR | 5 | 1.67 (1.02–2.73), adjusted |
Psychosis/ psychosis spectrum disorder | ||||
Molero et al., 2023 [5] | 27 June 2023 | Death, OR | 13 | 2.15 (1.68–2.75) |
Vai et al., 2021 [10] | 5 March 2021 | Death, OR | 4 | 2.05 (1.37–3.06) |
Schizophrenia | ||||
Pardamean et al., 2022 [3] | 15 November 2021 | Death, RR | 10 | 2.22 (1.54–3.20) |
Liu et al., 2021 [8] | 7 July 2021 | Death, OR | 8 | 2.28 (1.40–3.73) |
Mood disorder: depression and/or bipolar disorder | ||||
Molero et al., 2023 [5] | 27 June 2023 | Death, OR | 14 | 1.50 (1.31–1.71) |
Ceban et al., 2021 [6] | 1 February 2021 | Death, OR | 12 | 1.51 (1.34–1.69) |
Vai et al., 2021 [10] | 5 March 2021 | Death, OR | 6 | 1.99 (1.46–2.71) |
Neurodevelopmental disorder | ||||
Molero et al., 2023 [5] | 27 June 2023 | Death, OR | 2 | 1.26 (0.77–2.05) |
Anxiety disorder | ||||
Molero et al., 2023 [5] | 27 June 2023 | Death, OR | 6 | 1.14 (0.72–1.80) |
Liu et al., 2021 [8] | 7 July 2021 | Death, OR | 4 | 1.16 (0.75–1.79) |
Vai et al., 2021 [10] | 5 March 2021 | Death, OR | 3 | 1.07 (0.73–1.56) |
Substance use disorder | ||||
Molero et al., 2023 [5] | 27 June 2023 | Death, OR | 11 | 1.45 (1.12–1.87) |
Vai et al., 2021 [10] | 5 March 2021 | Death, OR | 4 | 1.76 (1.27–2.44) |
Opioid use disorder | ||||
Behnoush et al. 2022 [4] | December 2021 | Death, OR | 2 | 1.52 (1.27–1.82) |